59.36
1.02 (1.75%)
| Previous Close | 58.34 |
| Open | 58.20 |
| Volume | 2,120,897 |
| Avg. Volume (3M) | 2,914,204 |
| Market Cap | 11,237,982,208 |
| Price / Earnings (Forward) | 90.91 |
| Price / Sales | 3.88 |
| Price / Book | 4.69 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -36.06% |
| Operating Margin (TTM) | -11.53% |
| Diluted EPS (TTM) | -5.53 |
| Quarterly Revenue Growth (YOY) | 10.90% |
| Total Debt/Equity (MRQ) | 105.93% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 323.66 M |
| Levered Free Cash Flow (TTM) | 163.08 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -36.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Exact Sciences Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 98.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 85.00 (Craig-Hallum, 43.19%) | Buy |
| Median | 65.00 (9.50%) | |
| Low | 46.00 (RBC Capital, -22.51%) | Hold |
| Average | 63.86 (7.58%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 51.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 08 Oct 2025 | 70.00 (17.92%) | Buy | 59.32 |
| 11 Aug 2025 | 60.00 (1.08%) | Buy | 40.91 | |
| Evercore ISI Group | 07 Oct 2025 | 68.00 (14.56%) | Buy | 57.75 |
| 08 Aug 2025 | 64.00 (7.82%) | Buy | 40.99 | |
| Barclays | 02 Oct 2025 | 65.00 (9.50%) | Buy | 56.19 |
| 07 Aug 2025 | 55.00 (-7.35%) | Buy | 43.16 | |
| Craig-Hallum | 11 Sep 2025 | 85.00 (43.19%) | Buy | 56.00 |
| BTIG | 12 Aug 2025 | 60.00 (1.08%) | Buy | 41.74 |
| RBC Capital | 07 Aug 2025 | 46.00 (-22.51%) | Hold | 43.16 |
| UBS | 07 Aug 2025 | 53.00 (-10.71%) | Hold | 43.16 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DOYLE JAMES EDWARD | - | 59.46 | -2,000 | -118,920 |
| HERRIOTT JAMES | - | 59.46 | -1,500 | -89,190 |
| Aggregate Net Quantity | -3,500 | |||
| Aggregate Net Value ($) | -208,110 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 59.46 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DOYLE JAMES EDWARD | Director | 09 Oct 2025 | Automatic sell (-) | 2,000 | 59.46 | 118,920 |
| HERRIOTT JAMES | Officer | 09 Oct 2025 | Automatic sell (-) | 1,500 | 59.46 | 89,190 |
| Date | Type | Details |
|---|---|---|
| 08 Oct 2025 | Announcement | Exact Sciences Schedules Third Quarter 2025 Earnings Call |
| 07 Oct 2025 | Announcement | New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies |
| 22 Sep 2025 | Announcement | Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test |
| 10 Sep 2025 | Announcement | Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test |
| 19 Aug 2025 | Announcement | Exact Sciences to Participate in September Investor Conferences |
| 31 Jul 2025 | Announcement | Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |